Dydrogesterone
Modify Date: 2024-01-02 18:17:33
Dydrogesterone structure
|
Common Name | Dydrogesterone | ||
|---|---|---|---|---|
| CAS Number | 152-62-5 | Molecular Weight | 312.446 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 462.8±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H28O2 | Melting Point | 168-173°C | |
| MSDS | N/A | Flash Point | 172.2±25.7 °C | |
Use of DydrogesteroneDydrogesterone(Duphaston) is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.IC50 value:Target: Progesterone ReceptorDydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency. Although similar in molecular structure and pharmacological effects to endogenous progesterone. It is orally active at far lower doses. Its freedom from estrogenic, androgenic, anabolic, corticoid and other undesirable hormonal effects gives it additional benefits over most other synthetic progestogens.Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counteract the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone. |
| Name | dydrogesterone |
|---|---|
| Synonym | More Synonyms |
| Description | Dydrogesterone(Duphaston) is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency.IC50 value:Target: Progesterone ReceptorDydrogesterone is a potent, orally active progestogen indicated in a wide variety of gynaecological conditions related to progesterone deficiency. Although similar in molecular structure and pharmacological effects to endogenous progesterone. It is orally active at far lower doses. Its freedom from estrogenic, androgenic, anabolic, corticoid and other undesirable hormonal effects gives it additional benefits over most other synthetic progestogens.Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counteract the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 462.8±45.0 °C at 760 mmHg |
| Melting Point | 168-173°C |
| Molecular Formula | C21H28O2 |
| Molecular Weight | 312.446 |
| Flash Point | 172.2±25.7 °C |
| Exact Mass | 312.208923 |
| PSA | 34.14000 |
| LogP | 3.58 |
| Vapour Pressure | 0.0±1.1 mmHg at 25°C |
| Index of Refraction | 1.557 |
| Storage condition | Refrigerator |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Safety Phrases | S26-S37/39 |
|---|---|
| RIDADR | 3276 |
| WGK Germany | 3 |
| Packaging Group | III |
| Hazard Class | 6.1 |
|
~%
Dydrogesterone CAS#:152-62-5 |
| Literature: Recueil des Travaux Chimiques des Pays-Bas, , vol. 80, p. 43 - 46 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |
|
Coagulation and fibrynolitic parameters in women and the effects of hormone therapy; comparison of transdermal and oral administration.
Gynecol. Endocrinol. 29(2) , 165-8, (2013) It is established that hormone therapy (HT) is related with significant increased prothrombotic risk factor. The aim of our study was to assess the effects of oral hormone therapy (o-HT) and transderm... |
|
|
Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety.
Maturitas 76(1) , 10-21, (2013) HRT is known to be effective for the relief of menopausal symptoms and prevention of osteoporosis. HRT should be tailored to the woman, enhancing the beneficial effects of the treatment while minimizi... |
|
|
Hormone replacement therapy regimens in chemotherapy-induced premature ovarian failure and the subsequent correction of hormone levels.
Neuro Endocrinol. Lett. 33(7) , 697-702, (2012) Premature ovarian failure (POF) is a consequence of gonadotoxic chemoradiotherapy given in antyneoplasia treatment. In young women it will correlate with menopausal symptoms which tend to appear due t... |
| Dydrogesterone |
| D6-Retroprogesterone |
| δ6-Retroprogesterone |
| 9β,10α-Pregna-4,6-diene-3,20-dione (8CI) |
| 9b,10a-Pregna-4,6-diene-3,20-dione |
| (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one |
| (9β,10α)-Pregna-4,6-diene-3,20-dione |
| EINECS 205-806-8 |
| 6-Dehydro-9b,10a-progesterone |
| MFCD00867864 |
| 10a-Isopregnenone |
| 6-Dehydroretroprogesterone |
| 6-Dehydro-9β,10α-progesterone |
| (9b,10a)-Pregna-4,6-diene-3,20-dione |
| Pregna-4,6-diene-3,20-dione, (9β,10α)- |